Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes (T2D).1
Tirzepatide has been studied in a double-blind, randomised, phase 2 study in which patients with T2D were assigned (1:1:1:1:1:1) to receive either once-weekly subcutaneous tirzepatide (1 mg, 5 mg, 10 mg, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks.1
Tirzepatide showed significantly better efficacy in terms of glucose control and weight loss than did dulaglutide, with an acceptable safety and tolerability profile.1
How was this study conducted?
This analysis examined the metabolic profile of 259 patients from that cohort.
Plasma samples were analysed using a targeted mass spectrometry metabolomics approach.
Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-93.
This is a highlights summary of an oral session given at the EASD 2020 Virtual Meeting and presented by:
Valentina Pirro, MD
Eli Lilly, Indianapolis, IN, USA
The presenting authors of the original session had no part in the creation of this conference highlights summary.
The content is produced by Infomedica. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Florian Toti, MD, the scientific editor of the program.